FDA Approvals
Tracking FDA drug approvals and understanding their impact on VIALLMED HUB pharmaceutical rankings.
FDA Approval Tracking
FDA approval represents the culmination of years of clinical development and regulatory review. Approval rates and timelines are critical indicators of drug quality, safety, and commercial viability, making them high-weight factors in VIALLMED HUB CPI rankings.
Our platform monitors FDA approvals in real-time, tracking submission timelines, review processes, approval decisions, and post-market regulatory actions. This comprehensive view enables accurate assessment of regulatory success and market readiness.
FDA Approval Process
Pharmaceutical companies submit preclinical data to FDA requesting permission to begin human clinical trials. FDA reviews safety data, manufacturing information, and proposed trial protocols.
Drugs progress through three phases of clinical trials to demonstrate safety and efficacy. FDA monitors trials through regular reports and may request additional studies based on emerging data.
Companies submit comprehensive data packages including clinical trial results, manufacturing details, and proposed labeling. FDA conducts thorough review of all submitted data.
FDA review teams evaluate safety, efficacy, manufacturing quality, and labeling. Standard review takes 10 months; priority review for significant advances takes 6 months. Approvals may include conditions or restrictions.
After approval, FDA continues monitoring drug safety through adverse event reporting, Phase IV studies, and periodic safety updates. Approvals may be modified or withdrawn based on post-market data.
Approval Rate Impact
Average Approval Rate
CPI Rating Factor
Approved Drugs
FDA approval rates are one of the highest-weighted factors in VIALLMED HUB CPI rankings. Drugs with streamlined approvals and clean regulatory records demonstrate exceptional quality and regulatory confidence, significantly boosting their rankings.
Recent FDA Approvals
Explore the latest drug approvals filtered by country and company. Premium members can access full filtered data.
| Status | |||
|---|---|---|---|
Lung-ShieldSmall cell lung cancer | BeiGene | Jan 25, 2025 | Approved |
Pain-Relief ProChronic pain | Bausch Health | Jan 23, 2025 | Approved |
Derma-CarePsoriasis | Sanofi | Jan 22, 2025 | Approved |
Neuro-ProtectParkinson's disease | Novartis | Jan 21, 2025 | Approved |
Immuno-ForteLupus erythematosus | GlaxoSmithKline | Jan 20, 2025 | Approved |
Diabetes-ControlType 1 diabetes | Hengrui Medicine | Jan 19, 2025 | Approved |
Sakura-MedInflammatory bowel disease | Takeda | Jan 18, 2025 | Approved |
Onco-PrimeMelanoma | Roche | Jan 17, 2025 | Priority Review |
Cardio-ShieldAtrial fibrillation | AstraZeneca | Jan 16, 2025 | Fast Track |
ZephyrinNon-small cell lung cancer | Pfizer | Jan 15, 2025 | Approved |
Neuro-ZenAlzheimer's disease | Eisai | Jan 14, 2025 | Priority Review |
Immuno-GuardPsoriatic arthritis | Apotex | Jan 13, 2025 | Fast Track |
HepatixHepatitis C | Bayer | Jan 12, 2025 | Approved |
Onco-VitaProstate cancer | Ipsen | Jan 11, 2025 | Priority Review |
CardiomaxHeart failure with reduced ejection fraction | Johnson & Johnson | Jan 10, 2025 | Approved |
Thyroid-BalanceHypothyroidism | Abbott | Jan 9, 2025 | Approved |
NeurovanceMultiple sclerosis | Novartis | Jan 8, 2025 | Priority Review |
Migraine-AwayChronic migraine | Eli Lilly | Jan 7, 2025 | Priority Review |
Allergy-BlockSeasonal allergies | Mylan | Jan 6, 2025 | Approved |
Onco-GuardBreast cancer | Merck | Jan 5, 2025 | Fast Track |
Liver-ProtectNon-alcoholic steatohepatitis | Gilead | Jan 4, 2025 | Fast Track |
Arthritis-ReliefAnkylosing spondylitis | AbbVie | Jan 3, 2025 | Approved |
Hormone-BalancePolycystic ovary syndrome | Pfizer | Jan 2, 2025 | Approved |
Anxiety-CalmGeneralized anxiety disorder | Johnson & Johnson | Jan 1, 2025 | Approved |
Onco-ShieldColorectal cancer | Daiichi Sankyo | Dec 30, 2024 | Approved |
Blood-ControlSickle cell disease | Bristol Myers Squibb | Dec 29, 2024 | Approved |
RespironChronic obstructive pulmonary disease | AstraZeneca | Dec 28, 2024 | Approved |
Sleep-WellInsomnia | Merck | Dec 27, 2024 | Approved |
Infection-FighterBacterial pneumonia | Merck | Dec 26, 2024 | Priority Review |
Kidney-CareChronic kidney disease | Fresenius | Dec 25, 2024 | Approved |
Skin-HealAtopic dermatitis | Leo Pharma | Dec 24, 2024 | Approved |
Breast-ShieldHER2-positive breast cancer | Novartis | Dec 23, 2024 | Fast Track |
Vision-ClearMacular degeneration | Allergan | Dec 22, 2024 | Approved |
Prostate-CareBenign prostatic hyperplasia | Bayer | Dec 21, 2024 | Approved |
Immunex-4Rheumatoid arthritis | Roche | Dec 20, 2024 | Approved |
Lung-RestoreIdiopathic pulmonary fibrosis | Boehringer Ingelheim | Dec 19, 2024 | Approved |
Bone-StrongOsteoporosis | Amgen | Dec 18, 2024 | Approved |
Colon-GuardUlcerative colitis | Takeda | Dec 17, 2024 | Priority Review |
Memory-BoostMild cognitive impairment | Biogen | Dec 16, 2024 | Approved |
Diabetes PlusType 2 diabetes | Novo Nordisk | Dec 15, 2024 | Approved |
Heart-RhythmVentricular tachycardia | Medtronic | Dec 14, 2024 | Approved |
Eye-BrightDiabetic retinopathy | Regeneron | Dec 13, 2024 | Fast Track |
Bladder-ControlOveractive bladder | Astellas | Dec 12, 2024 | Approved |
Fever-DownFever and pain relief | Teva | Dec 11, 2024 | Approved |
Cholesterol-CutHypercholesterolemia | Amgen | Dec 10, 2024 | Approved |
Stomach-EaseGastroesophageal reflux disease | AstraZeneca | Dec 9, 2024 | Approved |
Bone-Marrow PlusMultiple myeloma | Celgene | Dec 8, 2024 | Priority Review |
Asthma-FreeSevere asthma | GlaxoSmithKline | Dec 7, 2024 | Approved |
Joint-FlexOsteoarthritis | Zimmer Biomet | Dec 6, 2024 | Approved |
Clot-BusterDeep vein thrombosis | Bayer | Dec 5, 2024 | Approved |
How Approvals Impact CPI Rankings
Approval Speed & Efficiency
Drugs that receive priority review or accelerated approval demonstrate exceptional clinical benefit and regulatory confidence. Faster approval timelines correlate with higher CPI ratings.
First-Time Approval Success
Applications approved without Complete Response Letters (CRLs) or major regulatory delays indicate superior data quality and regulatory preparedness, boosting CPI rankings significantly.
Post-Market Safety Record
Drugs maintaining clean post-market safety records without black box warnings, label changes, or regulatory actions demonstrate sustained quality and receive higher rankings.
Indication Expansion
Successful approval of additional indications or formulations demonstrates robust clinical versatility and regulatory success, providing incremental CPI boosts.
Official FDA Resources
Official FDA database of approved drugs with approval dates, labels, and regulatory history.
Visit FDA.gov →FDA's list of approved drug products with therapeutic equivalence evaluations.
Visit Orange Book →Learn More
For detailed information about how FDA approval data factors into our CPI rating algorithm, see our comprehensive Methodology page.
Questions about specific approval data or sources? Contact our research team at research@viallmedhub.com.